- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07945210
Colistin Heteroresistance in Multidrug-Resistant Gram-Negative Bacilli
Phenotypic and Genotypic Detection of Colistin Heteroresistance Among Multidrug-Resistant Gram-Negative Bacilli in Assiut University Hospitals
This cross-sectional study aims to detect colistin heteroresistance phenotypically and genotypically among multidrug-resistant Gram-negative bacilli isolated from clinical specimens at Assiut University Hospitals.
Study Overview
Status
Detailed Description
Multidrug-resistant Gram-negative bacterial infections are a major clinical concern. Colistin is used as a last-line therapy, but heteroresistance (presence of resistant subpopulations within a susceptible isolate) may lead to treatment failure and is difficult to detect by routine methods.
This observational study will collect multidrug-resistant Gram-negative isolates that are intermediate to colistin by broth microdilution and will test them for heteroresistance using population analysis profile as the reference method, in addition to gradient strips (Etest) and disc diffusion. Molecular detection of related resistance genes will also be performed.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Aliaa A Abdelrahman, Resident
- Phone Number: 01064480804
- Email: Aliaa.14223941@med.aun.edu.eg
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Multidrug-resistant Gram-negative bacterial isolates obtained from clinical specimens of hospitalized patients at Assiut University Hospitals.
Description
Inclusion Criteria:
- - Multidrug-resistant Gram-negative isolates from clinical specimens
- Colistin intermediate confirmed by broth microdilution
Exclusion Criteria:
- Gram-positive bacteria
- Carbapenem-sensitive Gram-negative bacteria
- Repeated samples from the same patient
- Colistin-resistant isolates confirmed by broth microdilution
Study Plan
How is the study designed?
Design Details
- Observational Models: CASE_ONLY
- Time Perspectives: CROSS_SECTIONAL
Cohorts and Interventions
Group / Cohort |
|---|
|
Multidrug-Resistant Gram-Negative Isolates
Clinical isolates of multidrug-resistant Gram-negative bacilli that are intermediate to colistin and will be tested for heteroresistance. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of isolates with colistin heteroresistance
Time Frame: Baseline
|
Number of multidrug-resistant Gram-negative isolates showing colistin heteroresistance by population analysis profile test. |
Baseline
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of isolates positive by Etest
Time Frame: Baseline
|
Number of isolates showing colistin heteroresistance by gradient strip (Etest) method. |
Baseline
|
|
Number of isolates positive by disc diffusion
Time Frame: Baseline
|
Number of isolates showing colistin heteroresistance by disc diffusion method. |
Baseline
|
|
Number of isolates carrying colistin heteroresistance-related genes
Time Frame: Baseline
|
Number of isolates positive for genes associated with colistin heteroresistance detected by conventional polymerase chain reaction. |
Baseline
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Mohamed Z Abdel-rahman, prof, Clinical pathology Department, Assiut University Hospitals
- Study Chair: Marwa M Mohammed, prof, Clinical pathology Department, Assiut University Hospitals
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Colistin-Heteroresistance-26
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.